Data was presented today showing that postmenopausal women who received ARIMIDEX (anastrozole) and Herceptin (trastuzumab) in combination had a significant improvement in progression-free survival when treated for advanced breast cancer that was both human epidermal growth factor receptor-2 (HER-2)-positive and hormone receptor-positive.
Married couples where breast cancer exists are in a risk situation when the cohesion level of the family is low, according to research carried out by the psychiatrist at the Family Diagnosis and Therapy Unit at the University Hospital of Navarra, Enrique Aub? Guedea.
Reducing dietary fat intake may decrease the chance of a breast cancer recurrence in women who have been treated for early-stage breast cancer, according to a randomized, phase III trial in the December 20 issue of the Journal of the National Cancer Institute.
Postmenopausal women with early-stage, hormone-sensitive breast cancer have a lower risk of disease recurrence when their treatment includes a new class of hormone therapy drugs, yet one out five women prescribed the drugs may not take them regularly, according to a study conducted by researchers at Dana-Farber Cancer Institute and AstraZeneca Pharmaceuticals.
Based on results recently presented at the 2006 San Antonio Breast Cancer Symposium, researchers speculate that a sudden decrease in the incidence of breast cancer in 2003 may be due to a reduction in the use of postmenopausal hormone therapy.
Nation-wide statistics indicate that while some types of cancer are occurring less frequently, the rates of others are still surging upward. According to a new study published in Annals of the New York Academy of Sciences, incidence of skin cancer is climbing in both sexes — more men are facing prostate cancer, while more women are diagnosed with breast cancer. Cancers showing a decrease in incidence in both sexes include lung, stomach and colon cancers.
New data from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-33 study, presented today at the San Antonio Breast Cancer Symposium, showed that postmenopausal women with hormone receptor-positive breast cancer who received Aromasin after five years of tamoxifen were 56 percent less likely to have a relapse of breast cancer than those who received placebo.
Expression of two different proteins taken from primary tumor biopsies is highly associated with spread of breast cancer to nearby lymph nodes, according to researchers who say this protein profile could help identify at an early stage those patients whose disease is likely to metastasize.
Scientists have discovered that induction of a gene known as MDA-7/IL-24 is the molecular mechanism that enables nonsteroidal anti-inflammatory drugs (NSAIDs) to halt the growth of cancer cells, a finding that could eventually lead to the development of targeted cancer treatments.
Scientists have revealed the critical role a key enzyme plays in helping cells divide in what could prove an important breakthrough for new cancer therapies.